Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    ACNS0821
Show Display Options
Rank Status Study
1 Active, not recruiting Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors
Conditions: Recurrent Childhood Medulloblastoma;   Recurrent Childhood Pineoblastoma;   Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
Interventions: Biological: Bevacizumab;   Drug: Irinotecan Hydrochloride;   Drug: Temozolomide

Indicates status has not been verified in more than two years